Drug Development/R&D

Recently published study by OHE, Brunel University, RAND Europe and Kings College London analyses time lags in medical research and where to shorten them.

The OHE gave the following presentations at ISPOR 17th Annual European Congress in Amsterdam, The Netherlands.

Launched at a seminar in his honour May 2014, Portrait of a Health Economist: Essays by Colleagues and Friends of Bengt Jönsson is an impressive collection of essays commemorating Bengt’s lifetime contribution to health economics. He was one of the true pioneers in the field – his 1976 doctoral thesis was on cost-benefit analysis in public health and medical care. He has since published hundreds of papers, reports and book chapters worldwide.

Cancer Research UK has recently released a report completed for it by OHE and the Science Policy Research Unit (SPRU) at the University of Sussex that focuses on the strength and nature of interdependence in the funding of cancer research. As earlier OHE research has demonstrated, sources of funding for medical research—public, charity and private sector—are complementary in effect, not duplicative.

Interviews with 19 senior pharma execs suggest how and to what extent effectiveness research may be integrated into drug development.
Changes in the clinical and economic milieu of health care systems worldwide are creating changes in the evidence required for both regulatory approval and reimbursement.

The OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing the new drugs.
A new model aimed at encouraging the development of new antibiotics was presented recently by OHE’s Chris Hoyle, who collaborated with Adrian Towse and Jorge Mestre-Ferrandiz in designing the model.

Under an MRC grant, OHE is collaborating to estimate in monetary terms the synergies of medical research spending in the UK by the pharma industry, charities and the public sector.

Focusing on England, these two presentations describe the core economic considerations in making the most of targeted therapy.
OHE's Adrian Towse participated in a two-day workshop convened by the Biotherapy Development Association to discuss the process and problems that surround decisions about pricing and reimbursement for innovative oncology medicines in Europe.

Progress in personalised medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in molecular diagnostics. In this open-access publication, OHE’s Adrian Towse and his co-authors examine nine case studies of diagnostics that have been successful in advancing personalised medicine.

Professor Adrian Towse, OHE’s Director, joined Professor Sir John Bell and Professor Andrew Morris at the Science Media Centre last week to launch Realising the Potential of Stratified Medicine, a new report by the UK’s Academy of Medical Sciences. Adrian and Professor Lou Garrison, OHE Visiting Senior Research Fellow, were two of a dozen experts who oversaw the preparation of the report.

Pages

Subscribe to RSS - Drug Development/R&D